For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Tumors modify the cellular metabolism in cancer cells when compared to normal healthy cells. They alter pathways of nutrient acquisition and metabolism to meet increased energy, synthetic, and proliferative demands. Biomarkers of tumor metabolism offer not only opportunities to study tumor progression but also to specifically assess therapies that target critical pathways in tumor metabolism. Our fluorescent imaging probes provide a variety of tools for quantifying key receptors associated with proliferation and nutrient uptake as well as biomarkers of cell death, protease activity, and vascular leak.
The availability of probes at 680 nm and 750 nm wavelengths further offer the opportunity for multiplex imaging of appropriate probe combinations to maximize information gained from research animals.
The Tumor Metabolism In Vivo Fluorescent Agents Panel includes the following seven probes:
|Part Number||Fluorescent Probe||Biological Target|
|NEV10054EX||AngioSense 680 EX||Vascular probe:
Leaks into sites of edema
|NEV10168||MMPSense 750 FAST||Pan-MMP activatable probe:
Secreted marker of neutrophils, macrophages, and mast cells
|NEV10003||ProSense 680||Pan-cathepsin activatable probe:
Lysosomal marker of a variety of inflammatory cells
|NEV10040||FolateRSense 680||Folate receptor targeted probe:
Marker on inflammatory cells; metabolic marker on tumor cells
|NEV10090||BombesinRSense 680||Bombesin receptor targeted probe:
Metabolic marker on tumor cells
|NEV10091||Transferrin-Vivo 750||Transferrin receptor targeted probe:
Iron metabolism marker on tumor cells
|NEV11053||Annexin-Vivo 750||Death/apoptosis probe:
Detects surface phosphatidylserine increase on dying cells
|Optical Imaging Classification||Fluorescence Imaging|
|Quantity in a Package Amount||7.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Tumor Metabolism|
|Unit Size||1 vial|
User guide for fluorescent imaging probes
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.